Clinical Trials
2 trialsNCT06477523 2026-04-29
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Sichuan University
Phase 1/2 Active not recruiting
NCT05116007 2024-05-31
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Akeso
Phase 1 Completed